semaglutide news 2025 fda compounding october Drug compounders sue over declaration ending Wegovy shortage FDA cracks down on weight-loss – Type 2 diabetes drug improves

Grab a spoon and eat at your own pace

Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

Biological Strategy Gila monster Sam Stier & AskNature Team Image: Andrew DuBois / Flickr / CC BY NC - Creative Commons Attribution + Noncommercial Regulate Cellular Processes Cells are the basic building blocks of all living systems, so cellular processes dictate how physiological processes occur within those systems

As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the Read More Fragmented Care in the GLP-1 Era: What Happens When Multiple Providers Prescribe the Same Therapy

The Data: Trials showed meaningful weight loss (around 8-10% depending on the study group), and it was helpful at assisting people in maintaining weight they had already lost on injections